Protalix: Rodman & Renshaw Global Investment Conference (Rodman and Renshaw 18th Annual Global Investment Conference 2016, Protalix) - Sep 18, 2016 - Anticipated initiation of P2 trial (NCT02768974) in mild to moderate ulcerative colitis by Q3 2017; Anticipated results from P2 trial in ulcerative colitis by Q3 2017
Anticipated P2 data • Anticipated trial initiation date • Biosimilar
|